Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Cancer Diagnostic Device

Published: Thursday, May 29, 2014
Last Updated: Thursday, May 29, 2014
Bookmark and Share
Commercial launch of a new system to improve cancer diagnosis and treatment.

This week sees the commercial launch of a new cancer diagnostic device developed by Clearbridge BioMedics in partnership with product development firm Cambridge Consultants.

The ClearCell FX System is able to isolate and capture circulating tumour cells (CTCs) from a blood sample - even at concentrations as low as one in a billion blood cells. This is crucial for both research and clinical purposes, as CTCs play a significant role in metastasis - the main cause of cancer-related deaths.

Cambridge Consultants helped to translate Singapore-based Clearbridge Biomedics’ design into a commercial prototype. “This commercial launch of the ClearCell FX System marks a new milestone in the project after a successful transfer from design and development to manufacturing,” said John Pritchard, head of diagnostics at Cambridge Consultants.

“It’s the latest example of our expertise in the design and development of diagnostic instrumentation, coupled with our long track record of helping clients bring innovative products to market fast. In this case it has helped create a device that has the potential to increase understanding of cancer - and, ultimately, improve patient care.”

The ClearCell FX System uses biomechanical properties to isolate intact, viable CTCs, making it label free - i.e. without biochemical markers. The fully-automated system integrates with downstream assays - making it simple to use and saving both time and manpower.

The device is highly sensitive and enables researchers to achieve reproducible results. It is designed to help cancer researchers better study CTCs and cancer metastasis biology - and potentially develop new cancer treatments.

With the ClearCell FX System, a simple blood test could provide clinicians and researchers with real-time monitoring of a patient’s cancer progression. This is critical as cancers are complex, heterogenous and constantly evolving with each treatment and over time.

“At Clearbridge BioMedics we aim to bring clarity to cancer, by allowing each and every patient to benefit from timely, tailored treatment,” said Johnson Chen, managing director of Clearbridge BioMedics. “Real-time monitoring of a patient’s CTCs allows clinicians to develop the best treatment at the right time. By matching treatments to the patient, they benefit from optimal treatment outcomes, with fewer negative side effects and lower costs.”

The ClearCell FX System is already being used by the Circulating Tumour Cell Centre of Research Excellence (CTC CoRE) - a collaboration between Clearbridge BioMedics, the National Cancer Centre Singapore and the pathology department at Singapore General Hospital.

"The ClearCell FX System allows us to reproducibly retrieve CTCs from a routine blood test, opening up new possibilities for applying molecular diagnostic tests that have become crucial in managing cancer patients,” said Dr Daniel Tan, consultant, Division of Medical Oncology at the National Cancer Centre Singapore.

“Beyond improving patient stratification, such minimally invasive tools provide unique vistas into studying the characteristics of cancer cells in circulation. It is anticipated that the CTC CoRE will bring together state-of-the-art microfluidic technologies, next-generation molecular diagnostics and cutting-edge clinical science - ultimately to improve cancer care.”

The ClearCell FX System will be showcased at the annual meeting of the American Society of Clinical Oncology (ASCO), May 30 to June 3, in Chicago.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Era in Cancer Diagnostics
Novel development for improved cancer diagnosis and treatment monitoring.
Tuesday, June 04, 2013
Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!